| DIRECT COMPETITOR COMPARISON | |
| PDLI | Pvt1 | SGEN | XOMA | Industry | | Market Cap: | 1.00B | N/A | 968.11M | 144.83M | 94.68M | | Employees: | 6 | 4881 | 261 | 335 | 65 | | Qtrly Rev Growth (yoy): | 3.80% | N/A | 44.20% | 247.40% | 19.70% | | Revenue (ttm): | 328.67M | 52.30M1 | 40.26M | 113.75M | 14.05M | | Gross Margin (ttm): | 100.00% | N/A | -217.41% | 44.09% | 64.07% | | EBITDA (ttm): | 303.04M | N/A | -100.69M | 45.60M | -12.30M | | Oper Margins (ttm): | 90.55% | N/A | -258.38% | 33.86% | -124.89% | | Net Income (ttm): | 216.58M | -38.50M1 | -100.16M | 7.55M | N/A | | EPS (ttm): | 1.153 | N/A | -1.168 | 0.051 | -0.32 | | P/E (ttm): | 7.26 | N/A | N/A | 14.27 | 17.01 | | PEG (5 yr expected): | 0.26 | N/A | N/A | N/A | 1.31 | | P/S (ttm): | 2.89 | N/A | 23.32 | 1.28 | 9.57 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.48 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SGEN | | Seattle Genetics to get $12M from Agensys
Mon, Nov 23 -
at bizjournals.com | | • | SGEN | | Seattle Genetics gets $12 million in Astellas deal
Mon, Nov 23 -
AP | | • | SGEN | | SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
Mon, Nov 23 -
EDGAR Online | | • | SGEN | | Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
Mon, Nov 23 -
Business Wire | | • | XOMA | | XOMA LTD /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra
Thu, Nov 19 -
EDGAR Online | | • | XOMA | | XOMA Receives NASDAQ Determination Letter
Thu, Nov 19 -
GlobeNewswire | | • | XOMA | | Coverage initiated on XOMA Limited by Canaccord Adams
Wed, Nov 18 -
Briefing.com | | • | XOMA | | XOMA Appoints Jim Neal Vice President of Business Development
Tue, Nov 17 -
GlobeNewswire | | • | SGEN | | Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
Mon, Nov 16 -
Business Wire | | • | XOMA | | Biotech Stock Mailbag: Cardium Therapeutics
Fri, Nov 13 -
at TheStreet.com | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
Competitors
